akb-9778
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01702441)
Timeline
Indications
Mechanism of action
PTPRB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- akb-9778
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04405245 | Phase 2 | Jun 30, 2020 | Aerpio Therapeutics |
| NCT04284514 | Phase 1 | May 2, 2019 | Aerpio Therapeutics |
| NCT03197870 | Phase 2 | Jun 1, 2017 | Aerpio Therapeutics |
| NCT02858271 | Phase 1 | Jul 1, 2016 | Aerpio Therapeutics |
| NCT02387788 | Phase 2 | Jan 1, 2015 | Aerpio Therapeutics, Johns Hopkins University |
| NCT02050828 | Phase 2 | Jan 1, 2014 | Aerpio Therapeutics |
| NCT01702441 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Aerpio Therapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aerpio Therapeutics | For profit | 7 | 7 | 2 | 2012 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1